IMR Press / FBL / Special Issues / molecular_depression

Molecular and Cellular Aspects of Depression

Submission deadline: 31 December 2025
Special Issue Editor
  • Lucia Carboni, PhD
    Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy
    Interests: mood disorders; peripheral biomarkers; Alzheimer's disease; nicotine dependence; drug discovery
Special Issue Information

Dear Colleagues,

Major depressive disorder is a major source of disease burden whose impact is continuing to rise. Indeed, the recent COVID-19 pandemic was accompanied by a major increase in the prevalence of cases worldwide. Beyond the morbidity and mortality associated with depression, this disorder is also linked to the exacerbation of other conditions. Although effective pharmacological and non-pharmacological interventions are available, approximately 30-60% patients are non-responsive or only partially responsive to treatment. The availability of response biomarkers could speed up recovery and spare patients the toxicity of ineffective treatments. Moreover, diagnostic biomarkers could assist with the diagnosis of depression, which currently relies solely on questionnaire tools. However, a better understanding of the biological basis of major depression is needed to develop new approaches to diagnosis and treatment. During the last 50 years, a number of mechanisms have been linked to the pathophysiology of major depression. These include monoaminergic dysregulation, hypothalamic–pituitary–adrenal axis dysfunction, impairment of neurogenetic and neurotrophic pathways, glutamatergic and GABAergic alterations, neuroinflammatory activation, and changes in neuropeptide signalling. Nevertheless, much still remains to be discovered and the identification of new targets for pharmacological intervention will require a much better comprehension of the molecular pathophysiological basis of major depressive disorder. This issue will report studies that shed new light on the molecular basis of major depression, as well as on peripheral biomarkers for personalized medicine. Studies in both humans and animal models are welcome.

Dr. Lucia Carboni
Guest Editor

Keywords
major depression
gene expression
transcriptomics
proteomics
epigenetics
signal transduction
animal models
post-mortem
biomarkers
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2600 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top